ArticlePediatric cardiology2026
Transcatheter Patent Foramen Ovale Closure and Complete Remission of Migraine in Children: A Single-Center Retrospective Cohort Study.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
To evaluate whether transcatheter patent foramen ovale (PFO) closure is associated with higher rates of complete migraine remission in children with migraine and a concomitant right-to-left shunt. We conducted a single-center retrospective cohort study of children with migraine and PFO-mediated right-to-left shunting. The primary exposure was transcatheter PFO closure; the primary outcome was complete migraine remission (no attacks for ≥ 3 consecutive months) assessed at 1, 3, 6, and 12 months post-discharge. Kaplan-Meier and multivariable Cox regression with a 3-month landmark were adjusted for right-to-left shunt (RLS) grade, age, sex, duration of the current headache episode, body mass index, and concomitant flunarizine prophylaxis. Among 66 children (mean age 10.3 years; 67% male), 19 underwent transcatheter PFO closure, and 47 received medical management. Complete migraine remission within 12 months occurred in 17/19 (89.5%) of closure patients versus 20/47 (42.6%) of non-closure patients (log-rank p = 0.002). In the adjusted Cox model, closure was associated with remission (hazard ratio [HR] 3.60, 95% confidence interval [CI] 1.38-9.42, p = 0.009); the association persisted after stratification for RLS (HR 3.18, 95% CI 1.26-8.04). A graded pattern was observed across three strata: no treatment 34.4%, flunarizine 60.0%, closure 89.5% (Kendall τ = 0.45, p < 0.001). All 19 procedures achieved complete closure without complications. Transcatheter PFO closure was associated with higher rates of complete migraine remission after adjustment for shunt grade, prophylaxis, and other covariates. Findings are hypothesis-generating; prospective randomized studies are needed before closure can be recommended for pediatric migraine outside clinical trials.
Indexed as
Identifiers
42184036What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.